The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
A retrospective analysis will be performed regarding the usefulness of PET/CT performed
 following 2 cycle of chemotherapy in evaluation of progression, free survival and overall
 survival of patients with aggressive non Hodgkin Lymphoma.
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing
 regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of
 chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT
 as a predictive value for progression free survival and overall survival is evaluated
Inclusion Criteria:

 -  aggressive non-Hodgkin lymphoma b cells

 -  age 18-70

 -  bilirubin less then 2

 -  creatinine less then 2

 -  Pet/CT performed post 2 cycles

 Exclusion Criteria:

 -  no PET/CT post 2 cycles performed

 -  bilirubin >2

 -  creatinine more then 2

 -  HIV positivity